Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity

DOI Web Site PubMed 7 Citations 42 References Open Access
  • Peter S. Lee
    Department of Molecular Biology and The Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037;
  • Reiko Yoshida
    Division of Global Epidemiology, Hokkaido University Research Center for Zoonosis Control, Sapporo 001-0020, Japan; and
  • Damian C. Ekiert
    Department of Molecular Biology and The Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037;
  • Naoki Sakai
    Institute of Biochemistry, Center for Structural and Cell Biology in Medicine and German Center for Infection Research, University of Lübeck, Lübeck 23538, Germany
  • Yasuhiko Suzuki
    Division of Global Epidemiology, Hokkaido University Research Center for Zoonosis Control, Sapporo 001-0020, Japan; and
  • Ayato Takada
    Division of Global Epidemiology, Hokkaido University Research Center for Zoonosis Control, Sapporo 001-0020, Japan; and
  • Ian A. Wilson
    Department of Molecular Biology and The Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037;

Search this article

Description

<jats:p>Continual and rapid mutation of seasonal influenza viruses by antigenic drift necessitates the almost annual reformulation of flu vaccines, which may offer little protection if the match to the dominant circulating strain is poor. S139/1 is a cross-reactive antibody that neutralizes multiple HA strains and subtypes, including those from H1N1 and H3N2 viruses that currently infect humans. The crystal structure of the S139/1 Fab in complex with the HA from the A/Victoria/3/1975 (H3N2) virus reveals that the antibody targets highly conserved residues in the receptor binding site and contacts antigenic sites A, B, and D. Binding and plaque reduction assays show that the monovalent Fab alone can protect against H3 strains, but the enhanced avidity from binding of bivalent IgG increases the breadth of neutralization to additional strains from the H1, H2, H13, and H16 subtypes. Thus, antibodies making relatively low affinity Fab interactions with the receptor binding site can have significant antiviral activity when enhanced by avidity through bivalent interactions of the IgG, thereby extending the breadth of binding and neutralization to highly divergent influenza virus strains and subtypes.</jats:p>

Journal

Citations (7)*help

See more

References(42)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top